Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
Giuliani, Rosa; Durbecq, Virginie; Di Leo, Angeloet al.
2007 • In European Journal of Cancer, 43 (4), p. 725-35
[en] AIM: Trastuzumab (T), a humanised monoclonal antibody against HER-2, is active in HER-2-positive MBC patients. However, nearly 60% of the patients do not benefit from T, stressing the need for additional predictive markers. The following markers could be implicated in response to T: (1) the magnitude of Her-2 gene amplification; (2) the co-expression of the other HER family receptors, possibly responsible for HER-2 trans-activation; (3) the activated status of HER-2; (4) the activated status of downstream effectors as mitogen-activated protein kinases (MAPKs), p38 and p27. METHODS: Medical files of patients with MBC treated with T either as a single agent or in combination with chemotherapy (CT) were reviewed. HER family members (EGFR, HER-2, HER-3, HER-4), the phosphorylated forms of EGFR (p-EGFR), HER-2 (p-HER-2) and of the downstream effectors were evaluated in the archival tumours. The correlation between clinical outcome and the expression of these markers was investigated. RESULTS: (1) Increasing values of Her-2 amplification were associated with a higher probability of achieving an objective response; (2) no statistical significant correlation between the expression of the HER family receptors was found; (3) p-HER-2 was predictive of response in patients treated with T+CT; (4) a statistically significant correlation between p-ERK 1/2, p-p38 and p-HER-2 emerged, pointing to the activated vertical pathway p-HER-2-->p-MAPKs. CONCLUSIONS: p-HER-2 and the magnitude of Her-2 amplification were predictive of response to T and their role deserves to be analysed in larger and more homogenous T-treated populations such as those from large phase III trials.
Disciplines :
Oncology
Author, co-author :
Giuliani, Rosa
Durbecq, Virginie
Di Leo, Angelo
Paesmans, Marianne
Larsimont, Denis
Leroy, Jean-Yves
Borms, Marleen
Vindevoghel, Anita
Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
Graus-Porta D., Beerli R.R., Daly J.M., and Hynes N.E. ErbB2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16 (1997) 1647-1655
Olayioye M.A., Neve M.R., Lane H.A., and Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19 (2000) 3159-3167
Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 (2001) S3-S8
Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001) 127-137
Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235 (1987) 177-182
Carter P., Presta L., Gorman C., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89 (1992) 4285-4289
Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999) 2639-2648
Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of T as single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. The Oncologist 9 Suppl. 3 (2004) 20-26
Baselga J., and Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12 Suppl. 1 (2001) 35-41
Baselga J., Albanell J., Molina M.A., and Arribas J. Mechanism of action of T and scientific update. Semin Oncol 28 Suppl. 16 (2001) 4-11
Molina M.A., Codony-Servat J., Albanell J., et al. T (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61 (2001) 4744-4749
Pegram M.D., and Reese D.M. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and Vascular Endothelial Growth Factor. Semin Oncol 29 Suppl. 11 (2002) 29-37
Cardoso F., Piccart M.J., Durbecq V., and Di Leo A. Resistance to T: a necessary evil or a temporary challenge?. Clin Breast Cancer 3 (2000) 247-255
Le X.-F., Pruefer F., and Bast R.C. HER-2 targeting antibodies modulate the cyclin-dependent kinase inhibitor p27kip1 via multiple signalling pathways. Cell Cycle 4 1 (2005) [Epub ahead of print]
Yakes M.F., Chinratanalab W., Ritter C., et al. Herceptin-induced inhibition of Phosphatidylinositol-3 Kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62 (2002) 4132-4141
Clark A.S., West K., Streicher S., and Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, T, or tamoxifen in breast cancer cells. Mol Cancer Ther 1 (2002) 707-717
Neve R.M., Lane H.A., and Hynes N.E. The role of overexpressed HER2 in transformation. Ann Oncol 12 Suppl. 1 (2001) S9-S13
Pegram M., Hsu S., Lewis G., et al. Inhibitory effects of combinations of HER2/neu antibody and chemotherapeutic agents used for treatment of human breast cancer. Oncogene 18 (1999) 2241-2251
Yu D., and Hung M.-C. Role of erbB2 in breast cancer chemosensitivity. BioEssays 22 (2000) 673-680
Baselga J., Norton L., Albanell J., Kim Y.-M., and Mendelsohn J. Recombinant humanised anti-HER2 antibody (Herceptin®) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58 (1998) 2825-2831
Lee S., Yang W., Lan K.-H., et al. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 62 (2002) 5703-5710
Tan M., Jing T., Lan K., et al. Phosphorylation on tyrosine-15 of p34cdc2 by ErbB2 inhibits p34cdc2 activation and is involved in resistance to taxol induced apoptosis. Mol Cell 23 3B (2002) 2275-2279
Yu D., and Hung M.-C. Therapeutic resistance of erbB-2-overexpressing cancers and strategies to overcome this resistance. In: Erlich M. (Ed). DNA alterations in cancer (2000), Eaton Publishing, Natick (MA) 457-470
Gancberg D., Di Leo A., Cardoso F., et al. Ann Oncol 13 (2002) 1036-1043
Naidu R., Yadav M., Nair S., and Kutty M.K. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 78 (1998) 1385-1390
Thor A.D., Liu S., Edgerton S., et al. Activation (tyrosine phosphorylation) of ErbB2 (HER2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol 15 (2000) 3230-3239
Albanell J., Rojo F., Averbuch S., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20 (2002) 110-124
Pohl G., Rudas M., Dietze O., et al. High p27kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus Goserelin. J Clin Oncol 21 (2003) 3594-3600
Tan P., Cady B., Wanner M., et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 57 (1997) 1259-1263
Catzavelos C., Bhattacharya N., Ung Y.C., et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3 (1997) 227-230
Wu J., Shen A.A., Lu J.S., et al. Prognostic role of p27Kip1 and apoptosis in human breast cancer. Br J Cancer 79 (1999) 1572-1578
Esteva F.J., Sahin A.A., Smith T.L., et al. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100 (2004) 499-506
Leake R., Barnes D., Pinder S., et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. J Clin Pathol 53 (2000) 634-635
Bell R., Verma S., Untch M., Cameron D., and Smith I. Maximizing clinical benefit with T. Semin Oncol 31 Suppl. 10 (2004) 35-44
Holbro T., Beerli R., Maurer F., et al. Proc Natl Acad Sci USA 100 (2003) 8933-8938
Hudelist G., Köstler W.J., Attems J., et al. Her-2/neu triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of T-based treatment. Br J Cancer 89 (2003) 983-991
Leyland-Jones B., Marty M., Baselga J., et al. HER2 extracellular domain (ECD) levels do not predict clinical response or time course of progression, in patients (pts) with metastatic breast cancer (MBC) or non-small cell lung cancer (NSCLC). Ann Oncol 15 (2004) [abstract 510]
Ali S.M., Esteva F.J., Fornier M., et al. Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy. Proc ASCO 24 (2006) [abstract 500]
Esteva F.J., Cheli C.D., Fritsche H., et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 7 (2005) R436-R443
Kostler W.J., Schwab B., Singer C.F., et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10 (2004) 618-624
Saez R., Molina M.A., Ramsey E., et al. p95HER-2 predicts worse outcome in patients with HER-2 positive breast cancer. Clin Cancer Res 12 (2006) 424-431
Yu D., Liu B., Yao J., et al. Overexpression of both p185erbB2 and p170mdr-1 renders breast cancer cells highly resistant to Taxol. Oncogene 16 (1998) 2087-2094
Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell-lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
Paez J.G., Jänne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefinitib therapy. Science 304 (2004) 497-1500
Sthephens P., Hunter C., Bignell G., et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431 (2004) 525-526
Nagata Y., Lan K.-H., Zhou X., et al. PTEN activation contributes to tumor inhibition by T, and loss of PTEN predicts T resistance in patients. Cancer Cell 6 (2004) 117-127
Chan-Hui P.-Y., Stephens K., Warnock R.A., et al. Applications of eTag assay platform to systems biology approaches in molecular oncology and toxicology studies. Clin Immunol 111 (2004) 162-174
Dowsett M., Gutierrez C., Mohsin S., et al. Molecular changes in tamoxifen-relapsed breast cancer: relationship between ER, HER2, and P38-MAP-kinase. Proc ASCO 22 (2003) [abstract 7]
